Evidence supporting the use of: Unsaturated fatty acid
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Unsaturated fatty acids, particularly omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their potential neuroprotective effects in Parkinson’s Disease (PD). Several preclinical studies in animal models indicate that omega-3 PUFAs may reduce neuroinflammation, oxidative stress, and dopaminergic neuron loss—key factors in PD pathology. Some small-scale clinical trials and observational studies suggest a correlation between higher dietary intake of unsaturated fatty acids and slower PD progression or reduced risk of developing PD. For example, a randomized controlled trial published in 2017 reported modest improvements in depression symptoms (a common PD comorbidity) with omega-3 supplementation, though effects on motor symptoms were less clear. However, robust clinical evidence directly supporting unsaturated fatty acids as a treatment or supportive therapy for PD is limited. Most studies are small, have methodological limitations, or focus on secondary outcomes rather than core PD symptoms. Current clinical guidelines do not recommend unsaturated fatty acids as a standard therapy for Parkinson’s Disease, but they are sometimes suggested as part of a healthy diet. In summary, while there is a scientific rationale and preliminary evidence, high-quality clinical validation is lacking, and the evidence supporting their use in PD is modest (rated 2/5).

More about Unsaturated fatty acid
More about Parkinson's Disease

Products containing Unsaturated fatty acid

We currently have no products on Vitabase that contain this ingredient.